KR20150132522A - 주요 전하 아이소폼이 풍부한 항체 조성물을 포함하는 신규 의약품 - Google Patents

주요 전하 아이소폼이 풍부한 항체 조성물을 포함하는 신규 의약품 Download PDF

Info

Publication number
KR20150132522A
KR20150132522A KR1020157029822A KR20157029822A KR20150132522A KR 20150132522 A KR20150132522 A KR 20150132522A KR 1020157029822 A KR1020157029822 A KR 1020157029822A KR 20157029822 A KR20157029822 A KR 20157029822A KR 20150132522 A KR20150132522 A KR 20150132522A
Authority
KR
South Korea
Prior art keywords
antibody
composition
monoclonal antibody
antibody composition
isoforms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157029822A
Other languages
English (en)
Korean (ko)
Inventor
길리암 세브류
니콜라스 바이호류
Original Assignee
라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 filed Critical 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스
Publication of KR20150132522A publication Critical patent/KR20150132522A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020157029822A 2013-03-15 2014-03-14 주요 전하 아이소폼이 풍부한 항체 조성물을 포함하는 신규 의약품 Withdrawn KR20150132522A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1352360 2013-03-15
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (1)

Publication Number Publication Date
KR20150132522A true KR20150132522A (ko) 2015-11-25

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029822A Withdrawn KR20150132522A (ko) 2013-03-15 2014-03-14 주요 전하 아이소폼이 풍부한 항체 조성물을 포함하는 신규 의약품

Country Status (11)

Country Link
US (1) US20160046722A1 (enExample)
EP (1) EP2968533A1 (enExample)
JP (1) JP2016512216A (enExample)
KR (1) KR20150132522A (enExample)
CN (1) CN105163758B (enExample)
AU (1) AU2014230134A1 (enExample)
BR (1) BR112015023209A8 (enExample)
CA (1) CA2907358A1 (enExample)
FR (1) FR3003171B1 (enExample)
MX (1) MX2015012812A (enExample)
WO (1) WO2014140322A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454547B2 (ja) 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
DK3451820T3 (da) 2016-05-04 2021-01-18 Delaval Holding Ab Kassette og konnektor til en pattekop samt pattekop, der omfatter kassetten og konnektoren
FR3053688B1 (fr) * 2016-07-06 2026-05-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
SG11202107941TA (en) 2019-01-23 2021-08-30 Encefa Cd31 competitors and uses thereof
US20200369720A1 (en) * 2019-05-23 2020-11-26 Regeneron Pharmaceuticals, Inc. Characterization of domain-specific charge variants of antibodies
WO2021057726A1 (zh) * 2019-09-23 2021-04-01 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209392B1 (pl) * 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CA2512729C (en) * 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP6454547B2 (ja) * 2011-07-06 2019-01-16 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節

Also Published As

Publication number Publication date
BR112015023209A2 (pt) 2017-07-18
JP2016512216A (ja) 2016-04-25
US20160046722A1 (en) 2016-02-18
EP2968533A1 (fr) 2016-01-20
FR3003171B1 (fr) 2015-04-10
CN105163758A (zh) 2015-12-16
AU2014230134A1 (en) 2015-10-29
CA2907358A1 (fr) 2014-09-18
FR3003171A1 (fr) 2014-09-19
MX2015012812A (es) 2016-05-09
BR112015023209A8 (pt) 2018-01-23
CN105163758B (zh) 2017-11-17
WO2014140322A1 (fr) 2014-09-18

Similar Documents

Publication Publication Date Title
KR20150132522A (ko) 주요 전하 아이소폼이 풍부한 항체 조성물을 포함하는 신규 의약품
TWI732176B (zh) 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
JP7504027B2 (ja) 互いに連結された２つの抗原結合ドメインを含む抗原結合分子
CN115942976A (zh) 掩蔽的il-2细胞因子和其切割产物
JP2021534196A (ja) 抗ｔｉｇｉｔ抗体
EP4214240B1 (en) Anti-ccr8 antibodies
JP7688579B2 (ja) 抗ｔｒｅｍ２抗体の使用方法
CN108619509A (zh) 抗体和蛋白酶的联合治疗应用
CN107660212A (zh) 抗‑cd303单克隆抗体
MX2013010210A (es) Lineas de celulas de bajo nivel de fucosa y usos de las mismas.
Wang et al. The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions
JP2016504337A (ja) イオン交換クロマトグラフィーを使用して高マンノースグリコフォームのレベルを制御する方法
CN117715940A (zh) 抗trem-1抗体
EP2660324A1 (en) Production of secreted therapeutic antibodies in microalgae
TWI920354B (zh) 抗ｃｃｒ８抗體
US20190002567A1 (en) New use of an anti-cd303 transmembrane protein antibody
RU2778053C2 (ru) Антитела к lag3
BR122024013309A2 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos
TW202611084A (zh) 抗ccr8抗體
KR20250108104A (ko) 개 pd-l1 항체, 이의 항원 결합 단편, 및 이의 사용 방법
WO2025214468A1 (zh) 抗il-15抗体以及其用途
HK40100657B (en) Anti-ccr8 antibodies
HK40100657A (en) Anti-ccr8 antibodies
CN119552247A (zh) 抗cd25抗体及其医药用途
BR122025022218A2 (pt) Anticorpo anti-ccr8 e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid